We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

211 hedge funds and large institutions have $3.11B invested in Cytokinetics in 2021 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 97 increasing their positions, 45 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more call options, than puts

Call options by funds: $16.7M | Put options by funds: $5.69M

116% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 45

115% more capital invested

Capital invested by funds: $1.45B → $3.11B (+$1.67B)

92% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 25

60% more funds holding in top 10

Funds holding in top 10: 5 → 8 (+3)

11% more funds holding

Funds holding: 190 → 211 (+21)

2.7% more ownership

Funds ownership: 105.38% → 108.08% (+2.7%)

Holders
211
Holders Change
+21
Holders Change %
+11.05%
% of All Funds
3.69%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.14%
New
48
Increased
97
Reduced
45
Closed
25
Calls
$16.7M
Puts
$5.69M
Net Calls
+$11M
Net Calls Change
+$6.59M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$118M
2
BlackRock
BlackRock
New York
+$47.4M
3
PHS
PFM Health Sciences
California
+$43.4M
4
Franklin Resources
Franklin Resources
California
+$29.4M
5
CAM
Cormorant Asset Management
Massachusetts
+$29.4M

Top Sellers

Rank Fund Capital Flow
1
MWNA
Marshall Wace North America
New York
-$32.4M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$14.1M
3
VC
Vivo Capital
California
-$13.9M
4
LGM
Logos Global Management
California
-$11.8M
5
IHAM
Integral Health Asset Management
New York
-$11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$28.3M +$5M +169,955 +27%
FCM
27
Frontier Capital Management
Massachusetts
$27M +$22.2M +755,438 New
Two Sigma Investments
28
Two Sigma Investments
New York
$24.3M +$7.9M +268,331 +65%
BCPEMI
29
Bain Capital Public Equity Management II
Massachusetts
$23.3M +$11.3M +384,347 +144%
HRCM
30
Hood River Capital Management
Florida
$22.3M +$18.4M +623,656 New
Charles Schwab
31
Charles Schwab
California
$21.9M +$2.95M +100,229 +20%
Principal Financial Group
32
Principal Financial Group
Iowa
$21.4M +$2.24M +76,150 +15%
OM
33
Opaleye Management
Massachusetts
$20.7M – – –
CS
34
Candriam SCA
Luxembourg
$18.3M – – –
Millennium Management
35
Millennium Management
New York
$18.2M +$1.71M +58,105 +13%
HM
36
HealthCor Management
New York
$15.5M -$9.27M -314,810 -42%
Invesco
37
Invesco
Georgia
$15.3M +$155K +5,263 +1%
SI
38
Sofinnova Investments
California
$15.2M -$1.61M -54,691 -11%
GPP
39
Great Point Partners
Connecticut
$14M +$11.5M +391,429 New
Ameriprise
40
Ameriprise
Minnesota
$12.6M +$1.13M +38,413 +12%
American Century Companies
41
American Century Companies
Missouri
$12.5M +$10.3M +348,993 New
Renaissance Technologies
42
Renaissance Technologies
New York
$12.1M +$7.88M +267,600 +378%
IHAM
43
Integral Health Asset Management
New York
$11.6M -$11M -375,000 -54%
PA
44
Pinnacle Associates
New York
$11.3M -$359K -12,180 -4%
Citadel Advisors
45
Citadel Advisors
Florida
$10.5M +$6.08M +206,533 +237%
PCM
46
Peregrine Capital Management
Minnesota
$10.3M -$3.99M -135,679 -32%
CM
47
CM Management
Florida
$9.83M -$1.47M -50,000 -15%
N
48
Nuveen
North Carolina
$9.57M +$739K +25,117 +10%
PPA
49
Parametric Portfolio Associates
Washington
$9.17M +$2.48M +84,307 +49%
AllianceBernstein
50
AllianceBernstein
Tennessee
$8.97M -$6.05M -205,592 -45%
1
2
3 4 5

CYTK Hedge Fund Activity: Q3 2021 in Review

211 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2021, worth a combined $3.11B — up 115% from $1.45B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new CYTK positions and 25 closed out — a net gain of 23 holders — while 97 added to existing stakes and 45 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $118M. The largest seller was Marshall Wace North America, cutting an estimated $32.4M.

  • 211 institutional investors held Cytokinetics (CYTK) as of Q3 2021, up from 190 in Q2 2021.
  • Funds reported $3.11B of Cytokinetics stock for Q3 2021, up 115% quarter-over-quarter.
  • 48 funds opened new Cytokinetics positions in Q3 2021 and 25 closed out, a net change of +23 holders.
  • The largest Cytokinetics buyer in Q3 2021 was Fidelity Investments, an estimated $118M added.
  • The largest Cytokinetics seller in Q3 2021 was Marshall Wace North America, an estimated $32.4M sold.

Based on aggregated 13F filings for Q3 2021.